Aldeyra Therapeutics to Participate in Upcoming Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

• Berenberg US CEO Conference
  Format: Analyst-Hosted Fireside Chat
  Date: Wednesday, November 10, 2021
  Time: 10:00 a.m. ET
  Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.

• Eyecelerator@AAO 2021
  Format: Retina Showcase Presentation
  Date: Thursday, November 11, 2021
  Time: 1:05 p.m. CT (2:05 p.m. ET)

• Jefferies London Healthcare Conference
  Format: Analyst-Hosted Fireside Chat
  Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021
  Note: A webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.

• Ophthalmology Day at BTIG
  Format: Analyst-Hosted Fireside Chat
  Date: Tuesday, November 30, 2021
  Time: 1:00 p.m. ET

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006224/en/

Corporate Contact:
Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
[email protected]

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
[email protected]

Source: Aldeyra Therapeutics, Inc.

You May Also Be Interested In

• TWO Announces Receipt of Final Regulatory Approval for Merger with CrossCountry Mortgage
• Evan Sandberg Wins 20th Annual Arizona State Poker Championship
• U.S. Marine Corps Awards Accrete Sole-Source Contract for Argus for Cognitive Advantage